Aldeyra to screen ADX-629, reproxalap for COVID-19 treatment

Aldeyra Therapeutics plans to screen its reactive aldehyde species inhibitors for anti-inflammatory and antiviral activity in the treatment of COVID-19, according to a press release.
The company’s ADX-629 and reproxalap are structurally related to chloroquine and hydroxychloroquine, the release said. Both drugs are currently in clinical testing for the treatment of COVID-19.
A proposal has been submitted to the Biomedical Advanced Research and Development Authority to develop ADX-629 for this purpose.
“We are committing scientific expertise and development resources associated with

Full Story →